Michael Allen Pulsipher, MD, Joins Children’s Hospital Los Angeles

Get Permission

Michael Allen Pulsipher, MD

Michael Allen Pulsipher, MD, joined the Children’s Center for Cancer and Blood Diseases and the Division of Hematology, Oncology, and Blood and Marrow Transplantation at Children’s Hospital Los Angeles (CHLA) as Head of the Section of Blood and Marrow Transplantation (BMT) and as BMT Clinical Research Chair. In addition, Dr. Pulsipher is a Professor of Pediatrics at the Keck School of Medicine of the University of Southern California (USC) and a Member of the USC Norris Comprehensive Cancer Center. These appointments became effective July 1, 2015.

The pediatric BMT Program at CHLA is one of the largest in the world, having performed more than 1,300 transplants since 1983. In directing the pediatric BMT program’s clinical care and clinical research activities, Dr. ­Pulsipher will closely collaborate in the further development of a leading research program that integrates laboratory and clinical science.

“Children’s Hospital Los Angeles is very excited to have Dr. Pulsipher join us in this important leadership position, as we work to develop more effective and less toxic therapies for children with cancer and blood diseases,” said Alan Wayne, MD, Director of the Children’s Center for Cancer and Blood Diseases and Division Head of Hematology, Oncology, and Blood and Marrow Transplantation at CHLA. “In addition to providing overall direction for our transplantation program, his research expertise will bring additional strength to our team of clinicians and scientists at CHLA who are leading the fight against refractory childhood leukemia.”

Dr. Pulsipher most recently served at Primary Children’s Hospital and the University of Utah School of Medicine in Salt Lake City. Among his many leadership roles, Dr. Pulsipher has served as Director of the Utah Blood and Marrow Transplant Program, as Medical Director of the Utah Cord Blood Program, and as current Group Chair of the Pediatric Blood and Marrow Transplant Consortium, an 80-member international clinical trials group. ■




By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.